Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phenolphthalein laxatives "medical value" consideration urged by Warner-Lambert.

This article was originally published in The Tan Sheet

Executive Summary

PHENOLPHTHALEIN LAXATIVES "MEDICAL VALUE" CONSIDERATION URGED by Warner-Lambert in a report submitted to FDA Aug. 26. Prepared by Felix de la Iglesia, MD, et al., Parke-Davis Pharmaceutical Research, the report recommends that "should regulatory agencies be willing to consider the extent of medical value of phenolphthalein and hence contribut[e] to a balance of the weight of evidence, some specific recommendations could be made to undertake studies over the next two to three years." FDA proposed banning the use of phenolphthalein in OTC laxatives Sept. 2 ("The Tan Sheet" Sept. 1, p. 1).
Advertisement

Related Content

Agoral Laxative With Senna Being Relaunched By Numark Labs
Agoral Laxative With Senna Being Relaunched By Numark Labs
Agoral Laxative With Senna Being Relaunched By Numark Labs

Topics

Advertisement
UsernamePublicRestriction

Register

PS087538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel